Otubanjo O A, Adeoye G O, Ibidapo C A, Akinsanya B, Okeke P, Atalabi T, Adejai E T, Braide E
Department of Zoology, University of Lagos, Akoka, Yaba, Lagos, Nigeria.
Rev Biol Trop. 2008 Dec;56(4):1635-43. doi: 10.15517/rbt.v56i4.5750.
Onchocerciasis is an endemic disease in Ondo state, Nigeria. Community directed distribution of ivermectin is currently on-going in some local government areas of the state. Randomly selected persons (2331 males and 2469 females) were interviewed using a modified rapid assessment procedure for Loa loa (RAPLOA) to assess community directed treatment with ivermectin. The retrospective study evaluated the coverage, impacts and adverse reactions to the drug treatment. A questionnaire was administered by house-to-house visit in six local government areas, implementing community directed treatment with ivermectin (CDTI) in this bioclimatic zone. A total of 2,398 respondents were reported to have participated in the treatment. The overall ivermectin coverage of 49.96% was recorded (range 0-52% in different communities). Adverse reactions from ivermectin administration were experienced in 38% of individuals. Diverse adverse reactions experienced included predominantly itching (18.50%); oedema, especially of the face and the limbs (8.2%); rashes (3.4%) and body weakness (2.4%). Expulsion of intestinal worms occurred in 0.96% of the respondents. The occurrence of adverse reactions in relation to age categories was statistically significant. Neither fatal nor severe adverse reactions were reported by respondents. Significantly, despite experienced adverse reactions, continued participation, acceptability and compliance to ivermectin treatment was expressed by the various communities. This attitude is in consonance with the African Programme for Onchocerciasis Control (APOC) objectives. Rev. Biol.
盘尾丝虫病是尼日利亚翁多州的一种地方病。目前该州一些地方政府辖区正在进行伊维菌素的社区定向分发。采用改良的罗阿丝虫快速评估程序(RAPLOA)对随机挑选的人员(2331名男性和2469名女性)进行访谈,以评估伊维菌素的社区定向治疗情况。这项回顾性研究评估了药物治疗的覆盖范围、影响及不良反应。通过逐户走访,在六个地方政府辖区实施了伊维菌素社区定向治疗(CDTI),该地区属于生物气候区。据报告,共有2398名受访者参与了治疗。伊维菌素的总体覆盖率为49.96%(不同社区的覆盖率范围为0 - 52%)。38%的个体出现了伊维菌素给药后的不良反应。出现的各种不良反应主要包括瘙痒(18.50%);水肿,尤其是面部和四肢水肿(8.2%);皮疹(3.4%)和身体虚弱(2.4%)。0.96%的受访者出现了肠道蠕虫排出的情况。不良反应在不同年龄组中的发生情况具有统计学意义。受访者均未报告致命或严重的不良反应。值得注意的是,尽管出现了不良反应,但各个社区仍表示会继续参与、接受并遵守伊维菌素治疗。这种态度与非洲盘尾丝虫病控制计划(APOC)的目标一致。《生物学评论》